stockrow
Friday 6 November 2026
Export LUNG’s income statement to Excel — free account
Pulmonx Corporation
LUNG Healthcare Medical Devices
Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024.
- Revenue
- +6.20%
- EPS
- +42.8%
- Free cash flow
- +61.3%
- Total debt
- +1.57%
Quarter to September 2026, against a year earlier
2.56
0.00
0.00%
Follow LUNG
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.93 | 0.63 | 0.61 | 0.99 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(25.91) | (10.59) | (5.35) | (12.69) | |
P/B ratio |
2.41 | 1.41 | 1.18 | 1.66 | |
Price to Tangible BV |
2.59 | 1.50 | 1.24 | 1.74 | |
EV/Sales |
0.76 | 0.42 | 0.33 | 0.63 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.63) | (1.20) | (1.01) | (1.76) | |
EV/FCF |
(2.63) | (1.19) | (1.00) | (1.74) | |
Quick Ratio |
3.13 | 3.35 | 3.84 | 4.09 | |
Current Ratio |
4.05 | 4.32 | 4.91 | 5.07 | |
Net Debt/EBITDA |
2.13 | 2.15 | 1.94 | 3.42 | |
Debt/Assets |
34.22% | 32.62% | 31.02% | 28.61% | |
Debt/Equity |
1.10 | 0.95 | 0.81 | 0.68 | |
Asset Turnover |
0.71 | 0.67 | 0.65 | 0.62 | |
Operating CF/Net income |
0.38 | 0.52 | 0.74 | 0.68 | |
Capex/Depreciation |
(0.02) | 0.00 | (0.03) | (0.05) | |
Interest Coverage |
(6.07) | (7.44) | (13.27) | (12.86) | |
Research and Development Expense of Revenue |
21.30% | 22.12% | 23.80% | 20.28% | |
Selling, General and Administrative Expense of Revenue |
87.69% | 95.65% | 117.07% | 101.16% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
15.81% | 16.25% | 20.09% | 18.77% | |
Graham Net Nets |
0.10 | 0.23 | 0.34 | 0.29 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(53.11%) | (89.23%) | (100.78%) | (60.18%) | |
Free Cash Flow Yield |
(31.05%) | (55.55%) | (54.42%) | (36.51%) | |
Revenue per Share |
0.53 | 0.54 | 0.49 | 0.56 | |
Operating CF per Share |
(0.07) | (0.12) | (0.24) | (0.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.12) | (0.24) | (0.17) | |
Cash per Share |
1.23 | 1.32 | 1.48 | 1.72 | |
Shareholders Equity per Share |
0.79 | 0.92 | 1.09 | 1.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.79 | 0.92 | 1.09 | 1.33 | |
Free Cash Flow |
(3.19) | (5.21) | (10.11) | (7.10) | |
Working Capital |
63.32 | 67.73 | 73.84 | 81.63 | |
Capital Expenditures |
(0.01) | 0.00 | (0.01) | (0.01) | |
Net Current Asset Value |
8.05 | 12.60 | 18.54 | 26.51 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.91 | 14.08 | 12.40 | 12.60 | |
Average Payables |
5.47 | 5.62 | 3.88 | 3.87 | |
Average Inventory |
15.84 | 16.28 | 16.56 | 16.38 | |
Average Assets |
124.25 | 130.96 | 135.35 | 146.07 | |
Average Common Equity |
47.12 | 54.14 | 61.71 | 69.96 |
Columns are period end dates · fundamentals updated 5 Nov 2026